Equities

cbdMD Inc

cbdMD Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.48
  • Today's Change-0.001 / -0.21%
  • Shares traded2.26k
  • 1 Year change-58.62%
  • Beta2.0164
Data delayed at least 15 minutes, as of Sep 20 2024 16:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

cbdMD, Inc. produces and distributes cannabidiol (CBD) products. The Company owns and operates CBD brands cbdMD, Paw CBD and cbdMD Botanicals. Its cbdMD brand of products includes a range of premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; drink mixes; and sleep, focus and calming aids.Its Paw CBD brand of products includes a line of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths and formulas. Its cbdMD Botanicals brand of beauty and skincare products features facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care stock-keeping units (SKU). cbdMD, Paw CBD and cbdMD Botanicals products are distributed through its e-commerce websites, third party ecommerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers. Its products are sold through www.cbdmd.com, www.pawcbd.com, and cbdmdbotanicals.com Websites.

  • Revenue in USD (TTM)20.64m
  • Net income in USD-23.42m
  • Incorporated2015
  • Employees52.00
  • Location
    cbdMD Inc8845 Red Oak BlvdCHARLOTTE 28217-5593United StatesUSA
  • Phone+1 (704) 445-3060
  • Websitehttps://www.cbdmd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CanaQuest Medical Corp0.00-812.13k1.05m-----------0.0517-0.05170.00-0.03720.00-------1,084.38--------------------------57.42------
Gold River Productions Inc.-100.00bn-100.00bn1.37m1.00k--2.12----------0.0005----------------------------0.00-------100.11------
60 Degrees Pharmaceuticals Inc441.25k-2.03m1.38m3.001.43----3.120.94550.94550.63362.980.07550.83552.09147,083.30-27.71------15.59---366.89--2.74--0.0505---50.40--35.51------
Nexien Biopharma Inc0.00-246.18k1.48m0.00---------0.0038-0.00380.00-0.00480.00-------679.40-860.53---1,653.53-----------1.77--------42.22------
Vestiage Inc0.00-39.63k1.51m0.00---------0.0007-0.00070.00-0.00150.00-------12,384.38---------------------------102.30------
Mallinckrodt PLC1.95bn-781.40m1.60m2.80k------0.0008-107.20-107.1884.9953.230.44891.634.95695,857.10-18.00-12.49-31.61-15.8530.3135.68-40.10-44.381.75-0.19010.6248---2.53-10.31-83.00------
Procyon Corp4.77m-387.79k1.62m17.00--0.764--0.3397-0.0478-0.04780.58910.27741.391.949.60280,817.70-10.813.52-13.694.2378.0173.30-7.782.522.22--0.00---3.223.1170.44--30.98--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Link Reservations Inc0.00-480.90k1.69m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
cbdMD Inc20.64m-23.42m1.81m52.00--0.5982--0.0877-18.95-18.957.850.80550.88172.0120.35396,856.90-82.98-38.59-112.36-41.5063.4363.80-94.12-87.980.5172-3.890.3128---31.77120.9163.64---4.95--
InVitro International716.89k6.22k2.05m16.00257.142.80--2.860.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Psyence Biomedical Ltd0.001.52m2.13m------1.41---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
SOHM Inc-100.00bn-100.00bn2.29m--------------------------------------------------------------
Altamira Therapeutics Ltd186.63k-2.10m2.55m10.00------13.67-27.55-27.550.2212-0.07460.04071.002.9618,663.44-45.74-68.57---117.99-8.39---1,124.78-26,516.341.79-12.18--------90.46------
Data as of Sep 20 2024. Currency figures normalised to cbdMD Inc's reporting currency: US Dollar USD

Institutional shareholders

2.26%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 30 Jun 202422.86k0.61%
The Vanguard Group, Inc.as of 30 Jun 202413.04k0.35%
Renaissance Technologies LLCas of 30 Jun 202412.61k0.34%
Two Sigma Securities LLCas of 30 Jun 202411.85k0.32%
BlackRock Fund Advisorsas of 30 Jun 202411.66k0.31%
Geode Capital Management LLCas of 30 Jun 202411.52k0.31%
RBC Dominion Securities, Inc.as of 30 Jun 2024625.000.02%
Tower Research Capital LLCas of 30 Jun 2024538.000.01%
Qube Research & Technologies Ltd.as of 30 Jun 2024300.000.01%
Harbour Investments, Inc.as of 30 Jun 2024159.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.